Exagen Inc.
XGN- 1M
- +1.8%
Exagen Inc. in brief
Exagen Inc. is a listed company in the Diagnostics and Research industry, based in Vista, California, USA. It was founded in 2002. Its market value was $218 M on 16 October 2026, which makes it the 15,928th largest listed company in the world and the 3,098th largest in the USA on this site. In the year to December 2025 it had sales of $67 M and a net loss of $20 M. It employs about 220 people and John Aballi is its chief executive. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol XGN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Exagen Inc.
We are a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under our AVISE® brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). We believe our strong focus and extensive background in the field of rheumatology, combined with our commitment to exceptional customer service and support, position us well to respond to the needs of rheumatologists, primary care physicians, other specialists, and the patients they serve.
From the company's annual report filed with the US SEC: read the report
Exagen Inc. timeline
- 2002
- 🏁· approximateFounded
- 2003
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- •Legal Entity Identifier issuedLEI 549300JV2CYDOME5OO17 registered.
- 2017
- ✎Renamed Exagen Inc.Formerly Exagen Diagnostics Inc.
- 2019
- 🔔· approximateInitial public offering on Nasdaq as XGN
- 2025
- 💰Record revenue of $67 millionFY2025, the highest of the 8 years on record.
Events of Exagen Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,829 (Jan 2020) · #3,363 (Jan 2021) · #3,979 (Jan 2022) · #4,934 (Dec 2022) · #4,850 (Jul 2023) · #4,232 (Jan 2024) · #2,026 (Mar 2026) · #3,208 (Aug 2026) · #3,096 (Sep 2026) · #3,102 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 3.0×
- Price / book
- 12.5×
- Free cash flow yield
- -6.5%
- Net margin (TTM)
- -25.1%
- Operating margin
- -21.1%
- Return on equity
- -104.2%
- Liabilities / assets
- 69.9%
- Net debt
- $-9M
- Revenue growth
- +19.7%
- R&D / revenue
- 9.4%
- Revenue per employee
- $303 K
- Profit per employee
- $-91 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $67M | +19.7% | $-14M | $-20M | -30.0% |
| Dec 2024 | $56M | +5.9% | $-14M | $-15M | -27.2% |
| Dec 2023 | $53M | +15.3% | $-23M | $-24M | -45.1% |
| Dec 2022 | $46M | -5.7% | $-46M | $-47M | -104.0% |
| Dec 2021 | $48M | +15.1% | $-24M | $-27M | -55.6% |
| Dec 2020 | $42M | +3.9% | $-15M | $-17M | -39.8% |
| Dec 2019 | $40M | +24.5% | $-9M | $-12M | -29.8% |
| Dec 2018 | $32M | — | $-5M | $-8M | -24.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-14M | $1M | $-14M | $-0.93 | — |
| Dec 2024 | $-13M | $1M | $-14M | $-0.83 | — |
| Dec 2023 | $-14M | $1M | $-15M | $-1.34 | — |
| Dec 2022 | $-32M | $4M | $-36M | $-2.77 | — |
| Dec 2021 | $-20M | $2M | $-23M | $-1.68 | — |
| Dec 2020 | $-14M | $0M | $-15M | $-1.32 | — |
| Dec 2019 | $-10M | $0M | $-10M | $-8.46 | — |
| Dec 2018 | $-9M | $0M | $-10M | $-293.34 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $18M (+6.8% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Aug 4, 202610-QQuarterly report · period to Jun 2026
- Aug 4, 20268-KCurrent reportResults of operations
- Jun 9, 20268-KCurrent reportShareholder vote
- May 11, 202610-QQuarterly report · period to Mar 2026
- May 11, 20268-KCurrent reportResults of operations
- Apr 27, 2026DEF 14AProxy statement
- Apr 23, 20268-KCurrent reportDirectors or officers changed
- Mar 10, 202610-KAnnual report · period to Dec 2025
- Mar 10, 20268-KCurrent reportResults of operations
- Jan 12, 20268-KCurrent reportResults of operations · Other events
Official filings of Exagen Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $67 M
- Operating income
- $-14 M
- Net income
- $-20 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $58 M
- Total liabilities
- $41 M
- Total equity
- $17 M
As of December-2025
Top 78 institutional investors in Exagen Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Parkman Healthcare Partners LLC | 926,548 | New | 3.63% | $8 M | Nov 16, 2026 |
| 2 | Wexford Capital LP | 759,835 | -33,020 (-4.16%) | 2.98% | $6 M | Nov 13, 2026 |
| 3 | Nano Cap New Millennium Growth Fund L P | 700,000 | +25,000 (+3.70%) | 2.74% | $6 M | Nov 13, 2026 |
| 4 | Vanguard Capital Management LLC | 623,907 | +11,075 (+1.81%) | 2.45% | $5 M | Nov 13, 2026 |
| 5 | Mink Brook Asset Management LLC | 531,673 | +55,729 (+11.71%) | 2.08% | $4 M | Nov 13, 2026 |
| 6 | First Eagle Investment Management, LLC | 516,098 | -97,832 (-15.94%) | 2.02% | $4 M | Nov 10, 2026 |
| 7 | Silvercrest Asset Management Group LLC | 469,457 | -45,304 (-8.80%) | 1.84% | $4 M | Nov 16, 2026 |
| 8 | Marshall Wace, LLP | 392,789 | +86,086 (+28.07%) | 1.54% | $3 M | Nov 13, 2026 |
| 9 | FourWorld Capital Management LLC | 352,543 | -243,985 (-40.90%) | 1.38% | $3 M | Nov 16, 2026 |
| 10 | Acadian Asset Management LLC | 311,482 | +1,398 (+0.45%) | 1.22% | $3 M | Nov 9, 2026 |
| 11 | Schonfeld Strategic Advisors LLC | 310,091 | New | 1.22% | $3 M | Nov 16, 2026 |
| 12 | Flputnam Investment Management Co | 299,828 | +11,018 (+3.81%) | 1.18% | $2 M | Nov 13, 2026 |
| 13 | Kennedy Capital Management LLC | 295,832 | -189,216 (-39.01%) | 1.16% | $2 M | Nov 13, 2026 |
| 14 | Citadel Advisors LLC | 273,804 | +259,411 (+1802.34%) | 1.07% | $2 M | Nov 16, 2026 |
| 15 | BlackRock, Inc. | 255,675 | +113,050 (+79.26%) | 1.00% | $2 M | Nov 13, 2026 |
| 16 | Man Group plc | 214,760 | +47,468 (+28.37%) | 0.84% | $2 M | Nov 16, 2026 |
| 17 | Gsa Capital Partners LLP | 200,600 | -14,121 (-6.58%) | 0.79% | $2 M | Nov 16, 2026 |
| 18 | Jane Street Group, LLC | 193,744 | -128,758 (-39.92%) | 0.76% | $2 M | Nov 12, 2026 |
| 19 | Geode Capital Management, LLC | 186,642 | +988 (+0.53%) | 0.73% | $2 M | Nov 6, 2026 |
| 20 | Two Sigma Investments, LP | 175,387 | +115,395 (+192.35%) | 0.69% | $1 M | Nov 16, 2026 |
| 21 | Susquehanna International Group, LLP | 151,661 | New | 0.59% | $1 M | Nov 16, 2026 |
| 22 | Squarepoint Ops LLC | 148,608 | +39,615 (+36.35%) | 0.58% | $1 M | Nov 9, 2026 |
| 23 | XTX Topco Ltd | 139,961 | +28,013 (+25.02%) | 0.55% | $1 M | Nov 16, 2026 |
| 24 | Millennium Management LLC | 127,817 | New | 0.50% | $1 M | Nov 16, 2026 |
| 25 | Perceptive Advisors LLC | 114,893 | 0 (0.00%) | 0.45% | $1 M | Nov 16, 2026 |
Show all 78: investors 26 to 78
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | D. E. Shaw & Co., Inc. | 106,268 | +56,556 (+113.77%) | 0.42% | $1 M | Nov 16, 2026 |
| 27 | Vanguard Fiduciary Trust Co | 101,846 | -6,803 (-6.26%) | 0.40% | $1 M | Nov 13, 2026 |
| 28 | Walleye Capital LLC | 96,196 | New | 0.38% | $1 M | Nov 13, 2026 |
| 29 | GWN Securities Inc. | 87,310 | +9,276 (+11.89%) | 0.34% | $1 M | Nov 12, 2026 |
| 30 | Trexquant Investment LP | 86,067 | New | 0.34% | $1 M | Nov 16, 2026 |
| 31 | Jump Financial, LLC | 81,714 | +69,989 (+596.92%) | 0.32% | $1 M | Nov 13, 2026 |
| 32 | State Street Corp | 79,356 | +8,100 (+11.37%) | 0.31% | $1 M | Nov 12, 2026 |
| 33 | BNP Paribas Financial Markets | 72,059 | +72,030 (+248379.31%) | 0.28% | $1 M | Nov 12, 2026 |
| 34 | SEI Investments Co | 65,091 | -43,914 (-40.29%) | 0.26% | $1 M | Nov 10, 2026 |
| 35 | Goldman Sachs Group Inc | 59,956 | +7,874 (+15.12%) | 0.23% | $0 M | Nov 16, 2026 |
| 36 | Qube Research & Technologies Ltd | 59,591 | New | 0.23% | $0 M | Nov 13, 2026 |
| 37 | Renaissance Technologies LLC | 59,382 | +19,782 (+49.95%) | 0.23% | $0 M | Nov 12, 2026 |
| 38 | Morgan Stanley | 55,312 | +48,974 (+772.70%) | 0.22% | $0 M | Nov 13, 2026 |
| 39 | Perkins Capital Management Inc | 55,296 | -1,500 (-2.64%) | 0.22% | $0 M | Nov 2, 2026 |
| 40 | Jpmorgan Chase & Co | 53,825 | +53,697 (+41950.78%) | 0.21% | $0 M | Nov 12, 2026 |
| 41 | Russell Investments Group, Ltd. | 51,458 | New | 0.20% | $0 M | Nov 6, 2026 |
| 42 | HRT Financial LP | 48,577 | +32,480 (+201.78%) | 0.19% | $0 M | Nov 13, 2026 |
| 43 | HSBC Holdings PLC | 46,703 | New | 0.18% | $0 M | Nov 16, 2026 |
| 44 | Quadrature Capital Ltd | 46,528 | New | 0.18% | $0 M | Nov 13, 2026 |
| 45 | Northern Trust Corp | 39,513 | 0 (0.00%) | 0.15% | $0 M | Nov 16, 2026 |
| 46 | Occudo Quantitative Strategies LP | 38,970 | +18,338 (+88.88%) | 0.15% | $0 M | Nov 16, 2026 |
| 47 | Bridgeway Capital Management, LLC | 29,596 | -406 (-1.35%) | 0.12% | $0 M | Nov 16, 2026 |
| 48 | Globeflex Capital L P | 24,619 | New | 0.10% | $0 M | Nov 16, 2026 |
| 49 | Empowered Funds, LLC | 24,396 | New | 0.10% | $0 M | Nov 13, 2026 |
| 50 | Algert Global LLC | 23,950 | New | 0.09% | $0 M | Nov 17, 2026 |
| 51 | Brevan Howard Capital Management LP | 21,777 | New | 0.09% | $0 M | Nov 16, 2026 |
| 52 | R Squared Ltd | 21,649 | -4,424 (-16.97%) | 0.08% | $0 M | Nov 6, 2026 |
| 53 | Bank of New York Mellon Corp | 20,938 | 0 (0.00%) | 0.08% | $0 M | Nov 5, 2026 |
| 54 | Arax Advisory Partners | 20,918 | 0 (0.00%) | 0.08% | $0 M | Nov 12, 2026 |
| 55 | Engineers Gate Manager LP | 19,932 | -17,068 (-46.13%) | 0.08% | $0 M | Nov 16, 2026 |
| 56 | Invesco Ltd. | 16,342 | -4,791 (-22.67%) | 0.06% | $0 M | Nov 12, 2026 |
| 57 | Point72 Asset Management, L.P. | 16,267 | New | 0.06% | $0 M | Nov 16, 2026 |
| 58 | Arrowstreet Capital, Limited Partnership | 14,550 | New | 0.06% | $0 M | Nov 13, 2026 |
| 59 | PDT Partners, LLC | 14,000 | New | 0.05% | $0 M | Nov 16, 2026 |
| 60 | Jain Global LLC | 12,263 | New | 0.05% | $0 M | Nov 16, 2026 |
| 61 | Bank Of America Corp /de/ | 11,707 | New | 0.05% | $0 M | Nov 16, 2026 |
| 62 | Calamos Advisors LLC | 11,518 | New | 0.05% | $0 M | Nov 2, 2026 |
| 63 | Penbrook Management LLC | 11,300 | New | 0.04% | $0 M | Oct 16, 2026 |
| 64 | Corient Private Wealth LP | 11,093 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 65 | Barclays PLC | 9,627 | +4,134 (+75.26%) | 0.04% | $0 M | Nov 6, 2026 |
| 66 | Vanguard Global Advisers, LLC | 8,408 | +4,267 (+103.04%) | 0.03% | $0 M | Nov 13, 2026 |
| 67 | UBS Group AG | 6,553 | +2,494 (+61.44%) | 0.03% | $0 M | Nov 10, 2026 |
| 68 | Citigroup Inc | 5,392 | New | 0.02% | $0 M | Nov 4, 2026 |
| 69 | Wells Fargo & Company/mn | 2,387 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 70 | Osaic Holdings, Inc. | 1,100 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 71 | Geneos Wealth Management Inc. | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 72 | Farther Finance Advisors, LLC | 990 | New | 0.00% | $0 M | Oct 8, 2026 |
| 73 | Rothschild Investment LLC | 600 | New | 0.00% | $0 M | Nov 10, 2026 |
| 74 | Group One Trading LLC | 586 | New | 0.00% | $0 M | Nov 10, 2026 |
| 75 | Jones Financial Companies Lllp | 200 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 76 | Latitude Advisors, LLC | 100 | New | 0.00% | $0 M | Oct 27, 2026 |
| 77 | Tower Research Capital LLC (TRC) | 98 | -2,870 (-96.70%) | 0.00% | $0 M | Nov 16, 2026 |
| 78 | Caitong International Asset Management Co., Ltd | 8 | -40 (-83.33%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Exagen Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 First Eagle Small Cap Opportunity FundFirst Eagle Investment Management, LLC | 435,574 | $2 M | 1.2% | 0.07% | +296% | Jul 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 414,852 | $2 M | 1.2% | <0.01% | −19% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 179,415 | $1 M | 0.50% | <0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 82,372 | $0 M | 0.23% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 55,958 | $0 M | 0.16% | 0.02% | +41% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 25,808 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 24,802 | $0 M | 0.07% | 0.08% | −34% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 22,903 | $0 M | 0.06% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 25,070 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 11,992 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 10,707 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 7,858 | $0 M | 0.02% | <0.01% | −9.3% | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 8,014 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 3,782 | $0 M | 0.01% | <0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 3,498 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 3,419 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 3,129 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 3,009 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 2,762 | $0 M | <0.01% | <0.01% | −24% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 1,831 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,605 | $0 M | <0.01% | <0.01% | −8.7% | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 1,000 | $0 M | <0.01% | <0.01% | −47% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 811 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 755 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 24 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Exagen Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jorey Chernett10% owner | Sell | -58,068 | $4.080 | $237 K | 2.53 M | Form 4 |
| filed | Jorey Chernett10% owner | Sell | -109,436 | $4.650 | $509 K | 2.59 M | Form 4 |
| filed | Jorey Chernett10% owner | Buy | +71,315 | $5.230 | $373 K | 2.70 M | Form 4 |
| filed | Jorey Chernett10% owner | Buy | +7,085 | $5.260 | $37 K | 2.63 M | Form 4 |
| filed | Jorey Chernett10% owner | Buy | +8,500 | $6.350 | $54 K | 2.62 M | Form 4 |
| filed | Jorey Chernett10% owner | Sell | -11,265 | $6.140 | $69 K | 2.61 M | Form 4 |
| filed | Jorey Chernett10% owner | Buy | +14,000 | $7.460 | $104 K | 2.62 M | Form 4 |
| filed | John AballiPresident and CEO, Director | Sell | -34,294 | $7.867 | $270 K | 805,540 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Exagen Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-183.62 reverse split
Fails to deliver
- : 5,600 shares at $8.56
- : 951 shares at $8.41
- : 67 shares at $7.58
- : 5,000 shares at $7.92
- : 1,103 shares at $7.43
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Exagen Inc. scorecard#
Passes 8 of the 22 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 16, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median12.5×Price to book 12.5× against Diagnostics and Research's median of 3.7×.
- ✓Price to sales below its peers' median3.0×Price to sales 3.0× against Diagnostics and Research's median of 4.5×.
- ✗Free cash flow yield above 5%-6.5%Free cash flow is -6.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 6
- ✓Revenue grew in the newest year19.7%Revenue up 19.7% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years13.5%13.5% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median13.5%13.5% a year against Diagnostics and Research's median of 3.6% (64 companies).
- ✗Earnings per share grew in the newest year-0.93 vs -0.83Diluted EPS -0.93 in fiscal 2025 against -0.83 the year before (report's currency).
- ✗Net income higher than five years earlier-$20 M-$20 M in fiscal 2025 against -$17 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-21.1%-21.1% against Diagnostics and Research's median of -2.4% (66 companies).
- ✗Return on equity above 15%-147.8%-147.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-21.1%-21.1% in fiscal 2025 against -101.1% in 2022.
Financial health2 of 5
- ✓Short-term assets cover short-term liabilities3.5×Current ratio 3.45 at the end of fiscal 2025.
- ✗Debt below equity1.3×Debt to equity 1.31 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $9 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-3.29Z-score -3.29 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year18.4%Diluted shares up 18.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Exagen Inc.'s statements, beside the median of Diagnostics and Research.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -21.1% | -2.4% | |
| Net margin | -30.0% | -3.6% | |
| Return on equity | -147.8% | -5.4% | |
| Revenue growth, 3 years a year | 13.5% | 3.6% | |
| Revenue growth | 19.7% | 6.6% | |
| Debt to equity | 1.31× | 0.57× |
3of 9on the Piotroski tests of financial strength
- Net loss of $20 million, the 8th loss-making year in a row.
- Free cash flow was negative: -$14 million.
- The share count rose 18.4% in the year.
- Revenue has grown 3 years in a row.
Exagen Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 67+19.7%100% | 56+5.9%100% | 53+15.3%100% | 46−5.7%100% | 48+15.1%100% | 42+3.9%100% | 40+24.5%100% | 32—100% | |
| Cost of revenue | 28+23.3%41.7% | 23−2.4%40.5% | 23−4.6%43.9% | 24+17.6%53.1% | 21+24.3%42.6% | 17−12.0%39.4% | 19+22.3%46.6% | 15—47.4% | |
| Gross profit | 39+17.2%58.3% | 33+12.4%59.5% | 29—56.1% | — | — | — | — | — | |
| Research and development | 6.3+16.4%9.4% | 5.4+10.5%9.7% | 4.9−50.7%9.3% | 9.9+36.5%21.7% | 7.2+103%15.0% | 3.6+64.0%8.5% | 2.2+2.4%5.4% | 2.1—6.6% | |
| Selling, general and administrative | 47+12.7%70.0% | 41−12.8%74.4% | 47−8.8%90.3% | 52+16.8%114% | 45+20.3%92.2% | 37+29.0%88.2% | 29+45.9%71.1% | 20—60.7% | |
| Total costs and expenses | 53+13.1%79.4% | 47−10.6%84.0% | 52r75−42.9%99.5% | 92+26.6%201% | 72+26.6%150% | 57+15.0%136% | 50+33.1%123% | 37—115% | |
| Operating income | −14—−21.1% | −14—−24.5% | −23—−43.5% | −46—−101% | −24—−49.8% | −15—−36.2% | −9.3—−23.0% | −4.9—−15.0% | |
| Interest and finance income | 0.3−62.3%0.4% | 0.8−49.4%1.4% | 1.5—2.9% | — | — | — | — | — | |
| Interest expense and finance costs | 4.3+93.3%6.5% | 2.2−4.3%4.0% | 2.3−4.6%4.4% | 2.4−6.7%5.4% | 2.6+2.3%5.4% | 2.6−26.5%6.1% | 3.5+21.7%8.6% | 2.9—8.8% | |
| Other non-operating income (expense) | — | — | — | — | 0.0−98.4%0.0% | 1.0+92.9%2.3% | 0.5+355%1.3% | 0.1—0.3% | |
| Income tax | 0.1+325%0.1% | 0.0−63.6%0.0% | 0.0—0.1% | −0.3−261%−0.6% | 0.2—0.4% | −0.1−416%−0.2% | 0.0−56.9%0.1% | 0.1—0.2% | |
| Net income attributable to shareholders | −20—−30.0% | −15—−27.2% | −24—−45.1% | −47—−104% | −27—−55.6% | −17—−39.8% | −12—−29.8% | −8.0—−24.7% | |
| Earnings per share, basic | -0.93—— | -0.83—— | -1.34—— | -2.77—— | -1.68—— | -1.32—— | -8.46—— | -293.34—— | |
| Earnings per share, diluted | -0.93—— | -0.83—— | -1.34—— | -2.77—— | -1.68—— | -1.32—— | -8.46—— | -293.34—— | |
| Shares, weighted average (basic) | 22+18.4%— | 18+3.0%— | 18+3.5%— | 17+7.0%— | 16+26.4%— | 13—— | — | — | |
| Shares, weighted average (diluted) | 22+18.4%— | 18+3.0%— | 18+3.5%— | 17+7.0%— | 16+26.4%— | 13+253%— | 3.6+5580%— | 0.1—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 32+46.2%55.5% | 22−39.6%49.3% | 36−41.5%64.1% | 62−37.3%72.4% | 99+73.1%80.6% | 57−20.3%73.3% | 72+448%81.6% | 13—45.6% | |
| Receivables | 11+38.5%18.7% | 7.8+18.7%17.5% | 6.6r6.6+8.2%11.6% | 6.1r6.1−37.1%7.1% | 9.7r9.7+8.9%7.9% | 8.9+55.9%11.4% | 5.7−4.0%6.5% | 6.0—20.6% | |
| Other current assets | 3.3−42.4%5.7% | 5.7+99.4%12.8% | 2.9+59.9%5.0% | 1.8+64.5%2.1% | 1.1−9.3%0.9% | 1.2−15.7%1.5% | 1.4+21.6%1.6% | 1.2—4.1% | |
| Current assets | 49+34.1%84.3% | 36−23.8%81.6% | 48−34.1%84.0% | 73−35.6%84.2% | 113+59.9%91.3% | 71−13.2%90.0% | 81+281%92.0% | 21—73.8% | |
| Property, plant and equipment | 6.9+31.3%12.0% | 5.3+1.6%11.8% | 5.2−36.5%9.1% | 8.2+71.8%9.5% | 4.8+127%3.9% | 2.1+52.3%2.7% | 1.4−11.9%1.6% | 1.6—5.4% | |
| Right-of-use (leased) assets | 1.4−40.2%2.5% | 2.4−26.9%5.4% | 3.3−32.7%5.8% | 4.9—5.7% | 0—0.0% | — | — | — | |
| Goodwill | — | — | — | 0−100%0.0% | 5.50.0%4.5% | 5.50.0%7.0% | 5.50.0%6.2% | 5.5—19.1% | |
| Total assets | 58+29.8%100% | 45−21.5%100% | 57−34.0%100% | 86−30.2%100% | 123+57.5%100% | 78−11.3%100% | 88+206%100% | 29—100% | |
| Accounts payable | 4.2+0.4%7.2% | 4.1+32.1%9.3% | 3.1+2.8%5.5% | 3.0+22.2%3.5% | 2.5−17.3%2.0% | 3.0+104%3.8% | 1.5+15.4%1.7% | 1.3—4.4% | |
| Debt due within a year | 0.6+52.0%1.1% | 0.4+60.2%0.9% | 0.3+38.9%0.5% | 0.2—0.2% | 0—0.0% | — | — | — | |
| Current liabilities | 14+4.8%24.4% | 14+13.5%30.2% | 12+23.7%20.9% | 9.6+3.3%11.2% | 9.3+6.2%7.5% | 8.8+48.8%11.2% | 5.9−34.1%6.7% | 9.0—31.0% | |
| Long-term debt | 22+12.3%38.4% | 20+3.1%44.4% | 19−33.2%33.8% | 29+4.7%33.4% | 27+3.1%22.3% | 27+3.1%34.0% | 26+5.0%29.3% | 25—85.2% | |
| Lease liabilities (non-current) | 0.4−73.7%0.8% | 1.7−39.7%3.7% | 2.8−38.6%4.8% | 4.5—5.2% | 0—0.0% | — | — | — | |
| Total liabilities | 41+15.4%69.9% | 35+2.6%78.7% | 34−21.7%60.1% | 44+13.6%50.8% | 39+5.4%31.2% | 37+11.9%46.6% | 33−8.3%37.0% | 36—123% | |
| Retained earnings | −314—−542% | −294—−659% | −279—−490% | −256—−296% | −208—−169% | −181—−231% | −165—−186% | −153—−528% | |
| Shareholders' equity | 17+82.9%30.1% | 9.5−58.0%21.3% | 23−46.6%39.9% | 42−50.0%49.2% | 85+103%68.8% | 42−24.8%53.4% | 56—63.0% | −112—−388% | |
| Total liabilities and equity | 58+29.8%100% | 45−21.5%100% | 57−34.0%100% | 86−30.2%100% | 123+57.5%100% | 78−11.3%100% | 88+206%100% | 29—100% | |
| Shares outstanding | 23+29.9%— | 18+3.5%— | 17+3.0%— | 17+2.4%— | 16+27.8%— | 13+0.7%— | 13+19836%— | 0.1—— | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | 2.1+23.5%3.2% | 1.7−22.7%3.1% | 2.2+37.5%4.2% | 1.6+77.8%3.5% | 0.9+80.0%1.9% | 0.5−16.7%1.2% | 0.60.0%1.5% | 0.6—1.8% | |
| Share-based compensation | 2.2+22.4%3.2% | 1.8−51.3%3.2% | 3.6−23.1%6.9% | 4.7−0.5%10.3% | 4.7+75.5%9.8% | 2.7+371%6.4% | 0.6+402%1.4% | 0.1—0.4% | |
| Cash from operating activities | −14—−20.5% | −13—−23.9% | −14—−27.5% | −32—−70.5% | −20—−42.0% | −14—−33.6% | −9.7—−24.0% | −9.3—−28.7% | |
| Capital expenditure | −0.6—−1.0% | −0.5—−0.9% | −0.8—−1.6% | −4.3—−9.5% | −2.4—−4.9% | −0.5—−1.1% | −0.4—−1.0% | −0.2—−0.6% | |
| Cash from investing activities | −0.6—−0.9% | −0.5—−0.9% | −0.8—−1.5% | −4.3—−9.5% | −2.4—−5.0% | −0.5—−1.1% | −0.1—−0.3% | −0.2—−0.6% | |
| Debt issued | — | — | — | — | — | — | 0−100%0.0% | 5.0—15.4% | |
| Debt repaid | — | 0—0.0% | −10—−19.0% | 0—0.0% | — | — | — | — | |
| Shares issued | 3.4—5.1% | 0—0.0% | — | 0−100%0.0% | 69—143% | 0—0.0% | — | — | |
| Cash from financing activities | 24—36.7% | −0.7—−1.2% | −11—−20.2% | −0.5−101%−1.1% | 65—134% | −0.1−100%−0.2% | 69+502%170% | 11—35.2% | |
| Change in cash | 10—15.3% | −14—−26.0% | −26—−49.3% | −37−188%−81.1% | 42—86.9% | −15−125%−34.9% | 59+2964%146% | 1.9—5.9% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 72+13.7%100% | 18+6.8%100% | 20+15.9%100% | 17+11.7%100% | 17*+21.8%100% | 17+37.9%100% | 17+14.2%100% | 15+7.5%100% | 14*−0.8%100% | 13—100% | 15—100% | 14—100% | 14*—100% | |
| Cost of revenue | 30+16.9%41.3% | 7.6+5.7%41.2% | 7.7+13.5%38.7% | 7.1+11.4%41.0% | 7.4*+43.4%44.6% | 7.2+29.7%41.6% | 6.8+13.3%39.6% | 6.4+9.6%41.1% | 5.2*−7.9%37.9% | 5.5—44.2% | 6.0—39.9% | 5.8—40.4% | 5.6*—40.8% | |
| Gross profit | 42+11.5%58.7% | 11+7.6%58.8% | 12+17.5%61.3% | 10+11.9%59.0% | 9.2*+8.6%55.4% | 10+44.3%58.4% | 10+14.8%60.4% | 9.1+6.1%58.9% | 8.5*—62.1% | 7.0—55.8% | 9.1—60.1% | 8.6—59.6% | — | |
| Research and development | 6.6+6.6%9.1% | 1.8+5.4%9.9% | 1.4−3.8%7.2% | 1.6+21.0%9.0% | 1.8*+6.1%10.6% | 1.7+16.8%10.0% | 1.5+25.8%8.6% | 1.3+21.2%8.3% | 1.7*+53.9%12.1% | 1.5—11.8% | 1.2—7.8% | 1.1—7.3% | 1.1*—7.8% | |
| Selling, general and administrative | 50+12.3%68.9% | 13+12.1%69.7% | 13+8.4%62.8% | 12+7.7%69.7% | 12*+21.8%74.7% | 11+12.6%66.4% | 12+10.3%67.1% | 11+6.3%72.3% | 10*−16.5%74.7% | 10—81.3% | 10—69.5% | 11—73.1% | 12*—88.7% | |
| Total costs and expenses | 57+12.7%78.8% | 15+15.7%82.8% | 14+7.0%69.9% | 14+9.1%78.7% | 14*+19.6%85.3% | 13+13.1%76.4% | 13+11.9%75.7% | 12+7.6%80.6% | 12*—86.9% | 12r17—93.1% | 12r18—77.3% | 12r17—80.5% | — | |
| Operating income | −15—−20.1% | −4.4—−23.9% | −1.7—−8.6% | −3.4—−19.7% | −5.0*—−29.9% | −3.1—−18.0% | −2.6—−15.3% | −3.4—−21.7% | −3.4*—−24.8% | −4.7—−37.3% | −2.6—−17.2% | −3.0—−20.8% | −5.1*—−37.4% | |
| Interest and finance income | — | — | — | — | 0.0*−78.2%0.3% | 0.0−98.5%0.0% | 0.1−53.0%0.5% | 0.2−17.7%1.0% | 0.2*+13.9%1.4% | 0.2—1.6% | 0.2—1.2% | 0.2—1.3% | 0.2*—1.3% | |
| Interest expense and finance costs | 5.0+40.8%6.9% | 1.2−8.9%6.5% | 1.2+6.9%6.0% | 1.3+132%7.3% | 1.3*+136%8.0% | 1.3+135%7.6% | 1.1+101%6.5% | 0.5−0.7%3.5% | 0.6*−0.5%4.1% | 0.6—4.5% | 0.6—3.7% | 0.5—3.8% | 0.6*—4.1% | |
| Other non-operating income (expense) | — | 0.2+5933%1.0% | 0.2+80.0%0.8% | −0.1−184%−0.8% | — | 0.0—0.0% | 0.1—0.5% | 0.2—1.0% | — | — | — | — | — | |
| Income tax | 0.0−4.0%0.1% | −0.0−200%−0.0% | 0−100%0.0% | 0.0—0.2% | 0.0*+8.3%0.1% | 0.0—0.0% | 0.0—0.2% | 0—0.0% | 0.0*—0.1% | 0—0.0% | 0—0.0% | — | — | |
| Net income attributable to shareholders | −18—−25.1% | −6.3—−34.4% | −3.2—−16.0% | −4.0—−22.9% | −4.7*—−28.1% | −7.1—−41.1% | −4.4—−25.8% | −3.8—−24.2% | −3.8*—−27.5% | −5.0—−40.2% | −3.0—−19.7% | −3.4—−23.3% | −5.6*—−40.5% | |
| Earnings per share, basic | — | -0.25—— | -0.13—— | -0.17—— | — | -0.31—— | -0.21—— | -0.20—— | — | -0.28—— | -0.16—— | -0.19—— | — | |
| Earnings per share, diluted | — | -0.25—— | -0.13—— | -0.17—— | — | -0.31—— | -0.21—— | -0.20—— | — | -0.28—— | -0.16—— | -0.19—— | — | |
| Shares, weighted average (basic) | 25+8.3%— | 25+8.3%— | 24+14.6%— | 24+28.5%— | — | 23+25.7%— | 21+16.0%— | 19+3.4%— | — | 18—— | 18—— | 18—— | — | |
| Shares, weighted average (diluted) | 25+8.3%— | 25+8.3%— | 24+14.6%— | 24+28.5%— | — | 23+25.7%— | 21+16.0%— | 19+3.4%— | — | 18—— | 18—— | 18—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 28—50.8% | 28−21.2%50.8% | 25−18.1%47.3% | 22+92.2%41.4% | 32+46.2%55.5% | 36+61.8%56.7% | 30+22.7%51.1% | 11−58.9%27.8% | 22−39.6%49.3% | 22—50.5% | 24—49.6% | 27—53.7% | 36—64.1% | |
| Receivables | 11—20.7% | 11+3.5%20.7% | 12−13.1%23.9% | 16+7.1%30.4% | 11+38.5%18.7% | 11+18.2%17.7% | 14+22.0%24.3% | 15+35.1%36.6% | 7.8+18.7%17.5% | 9.4—21.5% | 12—23.7% | 11—21.5% | 6.6r6.6—11.6% | |
| Other current assets | 4.1—7.3% | 4.1+15.4%7.3% | 4.2+11.1%8.0% | 4.1−13.7%7.9% | 3.3−42.4%5.7% | 3.5+20.1%5.6% | 3.7+30.3%6.4% | 4.7+126%11.8% | 5.7+99.4%12.8% | 2.9—6.7% | 2.9—5.8% | 2.1—4.1% | 2.9—5.0% | |
| Current assets | 45—81.9% | 45−13.8%81.9% | 43−15.9%82.5% | 44+34.1%83.9% | 49+34.1%84.3% | 53+47.9%83.7% | 51+25.0%86.8% | 33−23.3%80.7% | 36−23.8%81.6% | 36—81.5% | 41—82.7% | 42—83.5% | 48—84.0% | |
| Property, plant and equipment | 6.1—10.9% | 6.1−19.2%10.9% | 6.6+43.3%12.6% | 6.6+31.6%12.7% | 6.9+31.3%12.0% | 7.5+54.4%11.9% | 4.6−11.0%7.8% | 5.0+5.2%12.5% | 5.3+1.6%11.8% | 4.9—11.1% | 5.1—10.4% | 4.8—9.4% | 5.2—9.1% | |
| Right-of-use (leased) assets | 3.4—6.1% | 3.4+99.2%6.1% | 2.0+1.2%3.8% | 1.2−45.6%2.3% | 1.4−40.2%2.5% | 1.7−35.9%2.7% | 1.9−32.4%3.3% | 2.2−29.4%5.4% | 2.4−26.9%5.4% | 2.6—6.0% | 2.9—5.8% | 3.1—6.0% | 3.3—5.8% | |
| Total assets | 55—100% | 55−11.9%100% | 52−11.6%100% | 52+28.9%100% | 58+29.8%100% | 63+44.1%100% | 59+19.2%100% | 40−20.7%100% | 45−21.5%100% | 44—100% | 49—100% | 51—100% | 57—100% | |
| Accounts payable | 3.7—6.8% | 3.7+5.3%6.8% | 4.4+76.9%8.5% | 4.2−7.8%8.0% | 4.2+0.4%7.2% | 3.6+222%5.7% | 2.5+7.7%4.3% | 4.5+207%11.2% | 4.1+32.1%9.3% | 1.1—2.5% | 2.3—4.7% | 1.5—2.9% | 3.1—5.5% | |
| Debt due within a year | 0.5—0.8% | 0.5−33.4%0.8% | 0.5−22.5%1.0% | 0.6−77.1%1.1% | 0.6+52.0%1.1% | 0.7+58.1%1.1% | 0.7+57.7%1.1% | 2.5+846%6.3% | 0.4+60.2%0.9% | 0.4—1.0% | 0.4—0.9% | 0.3—0.5% | 0.3—0.5% | |
| Current liabilities | 13—23.7% | 13+1.6%23.7% | 13+30.7%25.9% | 13−10.2%24.2% | 14+4.8%24.4% | 13+46.9%20.5% | 10+9.0%17.5% | 14+59.3%34.7% | 14+13.5%30.2% | 8.8—20.1% | 9.4—19.2% | 8.8—17.3% | 12—20.9% | |
| Long-term debt | 22—40.4% | 22+0.4%40.4% | 22+0.1%43.0% | 22+21.1%42.9% | 22+12.3%38.4% | 22+12.3%35.4% | 22+12.5%38.0% | 18−4.5%45.7% | 20+3.1%44.4% | 20—45.5% | 20—40.2% | 19—37.9% | 19—33.8% | |
| Lease liabilities (non-current) | 2.6—4.7% | 2.6+240%4.7% | 1.1+5.9%2.2% | 0.1−91.9%0.2% | 0.4−73.7%0.8% | 0.8−61.1%1.2% | 1.1−52.1%1.8% | 1.4−45.2%3.4% | 1.7−39.7%3.7% | 2.0—4.5% | 2.2—4.5% | 2.5—4.9% | 2.8—4.8% | |
| Total liabilities | 42—75.1% | 42−7.0%75.1% | 40+5.3%76.5% | 38+10.7%72.2% | 41+15.4%69.9% | 45+45.4%71.1% | 38+18.9%64.2% | 34+10.0%84.1% | 35+2.6%78.7% | 31—70.5% | 32—64.3% | 31—60.7% | 34—60.1% | |
| Retained earnings | −328—−592% | −328—−592% | −321—−619% | −318—−613% | −314—−542% | −310—−493% | −303—−515% | −298—−740% | −294—−659% | −291—−666% | −286—−579% | −283—−556% | −279—−490% | |
| Shareholders' equity | 14—24.9% | 14−24.1%24.9% | 12−41.9%23.5% | 14+125%27.8% | 17+82.9%30.1% | 18+41.0%28.9% | 21+19.6%35.8% | 6.4−68.0%15.9% | 9.5−58.0%21.3% | 13—29.5% | 18—35.7% | 20—39.3% | 23—39.9% | |
| Total liabilities and equity | 55—100% | 55−11.9%100% | 52−11.6%100% | 52+28.9%100% | 58+29.8%100% | 63+44.1%100% | 59+19.2%100% | 40−20.7%100% | 45−21.5%100% | 44—100% | 49—100% | 51—100% | 57—100% | |
| Shares outstanding | 25—— | 25+12.9%— | 24+10.0%— | 24+34.2%— | 23+29.9%— | 23+28.5%— | 22+26.6%— | 18+3.6%— | 18+3.5%— | 18—— | 17—— | 17—— | 17—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 2.5+31.6%3.5% | 0.7+16.7%3.8% | 0.6+20.0%3.0% | 0.6+50.0%3.5% | 0.6*+50.0%3.6% | 0.6+50.0%3.5% | 0.5+25.0%2.9% | 0.4−20.0%2.6% | 0.4*−20.0%2.9% | 0.4—3.2% | 0.4—2.7% | 0.5—3.5% | 0.5*—3.6% | |
| Share-based compensation | 3.6+89.8%5.0% | 1.2+109%6.7% | 1.0+121%4.9% | 0.7+57.1%3.8% | 0.7*+62.8%4.2% | 0.6+173%3.4% | 0.4−20.9%2.6% | 0.4−24.6%2.7% | 0.4*−43.3%3.2% | 0.2—1.7% | 0.6—3.7% | 0.6—3.8% | 0.8*—5.5% | |
| Cash from operating activities | −12—−16.6% | −2.6*−187%−14.0% | 4.0*—20.0% | −10—−60.2% | −3.0*−930%−18.1% | 2.9*—17.1% | −2.9*—−16.8% | −11—−68.9% | 0.4*−95.7%2.7% | −2.2*—−17.4% | −2.4*—−16.1% | −9.0—−62.7% | 8.3*—60.7% | |
| Capital expenditure | −1.0—−1.4% | −0.2*—−1.1% | −0.5*—−2.7% | −0.2—−1.3% | −0.0*—−0.3% | −0.3*—−1.6% | −0.2*—−1.2% | −0.1—−0.7% | −0.1*—−1.1% | −0.1*—−1.2% | −0.1*—−0.9% | −0.1—−0.6% | −0.1*—−0.8% | |
| Cash from investing activities | −1.0—−1.4% | −0.2*—−1.1% | −0.5*—−2.7% | −0.2—−1.3% | −0.0*—−0.2% | −0.3*—−1.6% | −0.2*—−1.2% | −0.1—−0.7% | −0.1*—−1.1% | −0.1*—−1.2% | −0.1*—−0.9% | −0.1—−0.6% | −0.1*—−0.6% | |
| Debt repaid | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | |
| Shares issued | — | 6.4*—34.8% | — | — | −0.0*—−0.2% | −15*—−89.0% | — | — | 0*—0.0% | 0*—0.0% | — | — | — | |
| Cash from financing activities | 5.5−77.8%7.6% | 6.3*+113%34.1% | −0.4*−102%−1.9% | −0.1—−0.4% | −0.4*—−2.3% | 3.0*—17.1% | 22*—128% | −0.1—−0.4% | −0.2*—−1.6% | −0.1*—−1.0% | −0.2*—−1.5% | −0.1—−0.7% | −0.2*—−1.6% | |
| Change in cash | −7.6−156%−10.5% | 3.5*−37.6%19.0% | 3.1*−83.7%15.4% | −11—−61.9% | −3.4*−343300%−20.6% | 5.6*—32.6% | 19*—110% | −11—−70.0% | 0.0*−100.0%0.0% | −2.4*—−19.5% | −2.8*—−18.5% | −9.2—−64.0% | 8.0*—58.4% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Exagen Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable$67 M100%+20%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Exagen Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025John Aballi | $1.4 M | $2.9 M | $746 K | $253 |
| 2024John Aballi | $1.2 M | $2.0 M | $906 K | $168 |
| 2023John Aballi | $932 K | $775 K | $985 K | $82 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Exagen Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 5 · Material agreement 2 · New debt 1 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 14
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K/A | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
11 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2019 | $7 M | No. 11 | $2 to $10 million | 4 | equity | SEC |
| May 2017 | $4 M | No. 10 | $2 to $10 million | 4 | equity | SEC |
| Jan 2016 | $17 M | No. 9 | $10 to $50 million | 13 | equity | SEC |
| Oct 2015 | $3 M | No. 8 | $2 to $10 million | 4 | debt, options | SEC |
| Oct 2013 | $5 M | No. 7 | $2 to $10 million | 11 | equity | SEC |
| Sep 2012 | $5 M | No. 6 | $2 to $10 million | 7 | equity | SEC |
| Dec 2011 | $12 M | No. 5 | $10 to $50 million | 9 | equity | SEC |
| Sep 2011 | $5 M | No. 4 | $2 to $10 million | 8 | equity, debt | SEC |
| Jun 2011 | $5 M | No. 3 | $2 to $10 million | 8 | equity, options | SEC |
| Oct 2010 | $5 M | No. 2 | $2 to $10 million | 17 | equity, debt, options | SEC |
| May 2009 | $1 M | No. 1 | Under $2 million | 15 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Exagen Inc.#
$30 K spent on lobbying the US Congress and federal agencies in 2022, most often on medical/disease research/clinical labs.
- Medical/Disease Research/Clinical Labs3 reports
Lobbying firms hired in 2022
The Raben Group $30 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $30 K | — | 3 |
| 2021 | $20 K | — | 2 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Exagen Inc”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | · | · | · | · | · | · | · | · | · | · | · | 42 | 42 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 42 people | Restructuring planSEC 8-K | “The Company will reduce its current workforce by 42 employees (the “Reduction in Force”).” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Exagen Inc. compares in Diagnostics and Research
- Market cap$218 M · higher than 32% of 110
- Revenue$67 M · higher than 30% of 123
- Net margin-25.1% · higher than 25% of 112
- Revenue growth19.7% · higher than 75% of 89
- Price / sales3.0× · lower than 54% of 85
- Price / book12.5× · lower than 16% of 84
- FCF yield-6.5% · higher than 34% of 66
- 🇨🇦 Spectral Medical Inc.$217 M
- 🇮🇳 Vimta Labs Limited$226 M
- 🇬🇧 OneMedNet Corp$237 M
- 🇺🇸 Biodesix, Inc.$265 M
- 🇺🇸 Neuronetics, Inc.$162 M
- 🇺🇸 MaxCyte, Inc.$156 M
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Exagen Inc.🇺🇸 | $218 M | — | -25.1% | +19.7% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Spectral Medical Inc.$217 M
- Vimta Labs Limited$226 M
- OneMedNet Corp$237 M
- Biodesix, Inc.$265 M
- Neuronetics, Inc.$162 M
- MaxCyte, Inc.$156 M
Sources and freshness
- Market cap:
- Oct 16, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, Wikimedia Commons, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Exagen Inc.? Verify and update this profile — free
Show Exagen Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.